URETHAN since 1946 has been used extensively in the treatment of multiple myeloma with a good palliative response in somewhat more than 50% of the cases. The margin of safety in the use of this chemotherapeutic agent has appeared to be fairly broad. Moderate leucopenia and gastrointestinal symptoms are the most frequent complications. Rare reports have appeared of agranulocytosis and aplastic anemia in patients on urethan, and reversible central nervous system symptoms have been described, with improvement following cessation of therapy.6 In the past few years convincing evidence has accumulated from both experimental and clinical data indicating that in the dosage range required for effective therapy urethan may occasionally produce massive hepatic necrosis.* Five cases of acute massive centrilobular liver necrosis in patients with multiple myeloma on this treatment have been reported in the last five years.† Findings suggestive of renal damage produced by urethan have been reported in
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 13
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.